JUNO Juno Therapeutics, Inc.

24.87
0  -1%
Previous Close 25.10
Open 25.15
Price To book 2.41
Market Cap 2.57B
Shares 103,402,000
Volume 693,086
Short Ratio 8.12
Av. Daily Volume 1,618,560

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial to be initiated in 2017. ASCO Poster Session June 5, 2017. Abstract 7513.
JCAR017
r/r B cell non-Hodgkin lymphoma - cancer
Phase 1/2 ongoing
JCAR014
Adults with advanced B cell malignancies
Phase 2 clinical hold announced July 7, 2016. Clinical hold lifted July 12, 2016. Clinical hold placed back on - November 23, 2016. Announced March 1, 2017 that it will not continue development.
JCAR015
Relapsed/ refractory B cell acute lymphoblastic leukemia